Alamdari DH et al., 2020-08-20: Iranian phase I report: 25 ICU COVID-19 patients compared with 25 healthy individuals on nitrite, nitrate, methemoglobin and oxidative stress, after which five patients were given a methylene blue, vitamin C and N-acetyl cysteine combination as the last therapeutic option; four of the five responded well.
As the last therapeutic option, five patients were administered methylene blue-vitamin C-N-acetyl Cysteine (MCN).
Abstract
Alamdari DH et al., 2020-08-20: Iranian phase I report: 25 ICU COVID-19 patients compared with 25 healthy individuals on nitrite, nitrate, methemoglobin and oxidative stress, after which five patients were given a methylene blue, vitamin C and N-acetyl cysteine combination as the last therapeutic option; four of the five responded well. Study type: case series (5 treated patients) plus a 25 vs 25 observational comparison; described by the authors as a phase-I clinical trial. Country: Iran (Mashhad). Intervention: methylene blue + vitamin C + N-acetylcysteine (MCN) as a last-resort therapy; dose not in the abstract (the companion protocol paper specifies 50 mg MB, i.e. 1 mg/kg for a 50 kg adult, with 1000-2000 mg vitamin C and 500-1000 mg NAC in 100 mL D5W). Conflicts: 'There are no conflicts of interest in all authors.' No control arm for the treated patients; the 25 healthy comparators are not a disease control. Also filed as MTM-32 (claims C4, C6). Study type: uncontrolled series.
